专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

51. 发明申请

WO2021198341A1 ATP-DEPENDENT DNA LIGASE 审中-公开
公开(公告)号：WO2021198341A1
公开(公告)日：2021-10-07
申请号：PCT/EP2021/058452
申请日：2021-03-31
申请人： ARCTICZYMES AS
发明人： KETELSEN STRIBERNY, Bernd , SOLSTAD, Terese , LANES, Olav
IPC分类号： C12N9/00 , C12Q1/6855 , C12P19/34 , C12N15/52 , C12N9/93 , C12Y605/01001
摘要： The present invention relates to the field of ligases. More specifically it relates to novel and highly efficient ATP-dependent DNA ligases with a unique ligase activity making the ligase particularly useful in a variety of molecular biology techniques. Furthermore, the invention relates to compositions and kits comprising the DNA ligase, methods for its manufacture and use.

52. 发明申请

WO2021167497A1 ГЕНОТЕРАПЕВТИЧЕСКИЙ ДНК-ВЕКТОР 审中-公开
公开(公告)号：WO2021167497A1
公开(公告)日：2021-08-26
申请号：PCT/RU2021/000073
申请日：2021-02-20
申请人： ГЕНЕТИК ДИАГНОСТИКС ЭНД ТЕРАПИ 21 ЛТД , ОБЩЕСТВО, С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "РЕКОМБИТЕХ"
发明人： ГАМОЛСКИ, Антон
IPC分类号： C12N15/12 , C12N15/70 , C12N1/21 , C12N9/00 , A61P37/02 , A61P35/00
摘要： Создан генотерапевтический ДНК -вектор на основе генотерапевтического ДНК-вектора GDTT1.8NAS12 для лечения заболеваний, характеризующихся нарушением врожденного и адаптивного иммунитета, для терапии аутоиммунных, онкологических, вирусных заболеваний, связанных с дисбалансом иммунной системы, для иммуномодуляции в том числе при противоопухолевой вакцинации в качестве генотерапевтического адъюванта. Генотерапевтический ДНК- вектор GDTT 1.8NAS 12-IFNB 1 содержит кодирующую часть целевого гена IFNB1, генотерапевтический ДНК -вектор GDTT1.8NAS12-IFNA14 содержит кодирующую часть целевого гена IFNA14, генотерапевтический ДНК-вектор GDTT 1.8NAS 12-IFNA2 содержит кодирующую часть целевого гена IFNA2, генотерапевтический ДНК-вектор GDTT1.8NAS12-IL12A содержит кодирующую часть целевого гена IL12A, генотерапевтический ДНК-вектор GDTT1.8NAS12-IL12B содержит кодирующую часть целевого гена IL12B. Каждый из созданных генотерапевтических ДНК-векторов за счет ограниченного размера векторной части GDTT1.8NAS12, не превышающей 2600 и. н., обладает способностью эффективно проникать в клетки человека и животных и экспрессировать клонированный в него целевой ген IFNB1, или IFNA14, или IFNA2, или IL12A, или IL12B.

53. 发明申请

WO2021163555A1 LOSS OF TET PROTEINS IN REGULATORY T CELLS UNLEASHES EFFECTOR FUNCTION 审中-公开
公开(公告)号：WO2021163555A1
公开(公告)日：2021-08-19
申请号：PCT/US2021/017949
申请日：2021-02-12
申请人： LA JOLLA INSTITUTE FOR IMMUNOLOGY
发明人： RAO, Anjana , HOGAN, Patrick , YUE, Xiaojing , SEI, Jyungseok
IPC分类号： C12N5/0783 , A61K35/17 , A61P35/00 , C12N9/00
摘要： The present invention includes methods and compositions for converting regulatory T cells (Tregs) into Ten-Eleven Translocation (TET) deficient Treg cells (ex-Treg) in vitro comprising: isolating Tregs from a subject; and culturing the Tregs with an agent that inhibits the activity or expression of one or more TET enzymes in the Tregs, wherein the loss of TET enzyme function converts the Tregs into ex-Tregs.

54. 发明申请

WO2021142393A1 BIOSYNTHETIC PLATFORM FOR THE PRODUCTION OF OLIVETOLIC AVID AND ANALOGUES OF OLIVETOLIC ACID 审中-公开
公开(公告)号：WO2021142393A1
公开(公告)日：2021-07-15
申请号：PCT/US2021/012866
申请日：2021-01-09
申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
发明人： TANG, Yi , CHEN, Mengbin , OKORAFOR, Ikechukwu
IPC分类号： C12N15/52 , C12N15/70 , C12N9/00
摘要： The disclosure provides biosynthetic platforms that generate olivetolic acid and its analogues at high titers from microbes, and in cell free systems.

55. 发明申请

WO2021142192A1 MICROPARTICLE-BASED ENZYME SYSTEMS FOR SELECTIVE REMOVAL OF TARGET MOLECULES 审中-公开
公开(公告)号：WO2021142192A1
公开(公告)日：2021-07-15
申请号：PCT/US2021/012599
申请日：2021-01-08
申请人： SYNLIFE, INC.
发明人： MOSER, Felix , BENJAMIN, David
IPC分类号： A61K38/44 , C12N9/00 , A61K9/127 , A61P39/00 , C12Y106/03001
摘要： The present disclosure provides compositions of microparticles and uses thereof for removing toxic or undesirable molecules from an environment, e.g. the blood of a subject. The microparticles can be liposomes. In one embodiment, the aqueous phase of the liposomes contains (i) a system of generating NAD+ from NADH, and (ii) one or more enzymes that are involved in one or more NAD+- dependent reactions that remove the toxic or undesirable molecules from the environment. In one embodiment, the liposomes contain NADH oxidase, alcohol dehydrogenase (ADH) and acetaldehyde dehydrogenase (ALDH) to remove ethanol from the blood of a subject.

56. 发明申请

WO2021125917A1 WHEP 도메인 융합에 의한 목적 단백질의 수용성 증진 방법 审中-公开
公开(公告)号：WO2021125917A1
公开(公告)日：2021-06-24
申请号：PCT/KR2020/018837
申请日：2020-12-21
申请人： 연세대학교 산학협력단
发明人： 성백린 , 이진희 , 김영석 , 정유철
IPC分类号： C12N9/00 , C07K14/565 , C12N9/48 , C12N15/70 , C12P21/00
摘要： 본 발명은 목적 단백질의 발현 효율을 증진시키기 위한 융합 단백질에 관한것이다. 보다 상세하게는, hEPRS(Glutamyl-prolyl-tRNA synthetase from human)의 WHEP 도메인(EPRS 단백질의 중간 부분에 위치한 WHEP 도메인 TRS-1, TRS-2, TRS-3와 세 도메인을 연결하는 링커를 포함함)이다. 본 발명에 따른 hEPRS의 WHEP 도메인은 목적 단백질의 대장균에서의 발현을 위해 융합 단백질로 사용될 때, 목적 단백질의 수용성이 향상되었다.

57. 发明申请

WO2021112266A1 산화적 스트레스를 저감하고 사료효율을 개선하는 동물 사료용 첨가제 및 이의 제조방법 审中-公开
公开(公告)号：WO2021112266A1
公开(公告)日：2021-06-10
申请号：PCT/KR2019/016841
申请日：2019-12-02
申请人： 주식회사 건풍바이오
发明人： 오천금 , 김성철 , 오정배
IPC分类号： A23K20/00 , A23K20/163 , A23K20/174 , A23K10/14 , C12N9/00
摘要： 본 발명은 백년초 추출액 혹은 착즙액과, 키토산올리고당을 함유하는 것을 특징으로 하는 사료 첨가제를 제공한다.

58. 发明申请

WO2021102390A1 RECOMBINASE COMPOSITIONS AND METHODS OF USE 审中-公开
公开(公告)号：WO2021102390A1
公开(公告)日：2021-05-27
申请号：PCT/US2020/061705
申请日：2020-11-22
申请人： FLAGSHIP PIONEERING INNOVATIONS VI, LLC [US]/[US]
发明人： RUBENS, Jacob, Rosenblum , CITORIK, Robert, James , CLEAVER, Stephen, Hoyt , COTTA-RAMUSINO, Cecilia, Giovanna, Silvia , FU, Yanfang
IPC分类号： C12N15/11 , C07K14/005 , C12N15/33 , C12N9/22 , C12N5/10 , C12P19/34 , C12N15/86 , C12N2750/14143 , C12N2830/38 , C12N2830/46 , C12N9/00 , C12Y306/04
摘要： Methods and compositions for modulating a target genome are disclosed.

59. 发明申请

WO2021094465A1 POLYPEPTIDE MONOMÉRIQUE PRÉSENTANT UNE ACTIVITÉ HYDROGÉNASE, EN PARTICULIER POLYPEPTIDE MONOMÉRIQUE RECOMBINANT PRÉSENTANT UNE ACTIVITÉ HYDROGÉNASE 审中-公开
公开(公告)号：WO2021094465A1
公开(公告)日：2021-05-20
申请号：PCT/EP2020/081931
申请日：2020-11-12
申请人： H2WIN S.A.
发明人： GODAUX, Damien , LORGE, Philippe , GHYSELS, Bart , JOB, Nathalie , FRANCK, Fabrice , CALDARELLA, Giuseppe , CARDOL, Pierre , REMACLE, Claire
IPC分类号： C12N9/00 , C12N9/02 , C12P3/00
摘要： La présente invention porte sur un polypeptide monomérique comportant une seule sous-unité comprenant le site actif d'une protéine de type [NiFe]-hydrogénase, ledit polypeptide monomérique présentant une activité hydrogénase.

60. 发明申请

WO2021089984A1 CRISPR-MEDIATED IDENTIFICATION OF BIOTINYLATED PROTEINS AND CHROMATIN REGIONS 审中-公开
公开(公告)号：WO2021089984A1
公开(公告)日：2021-05-14
申请号：PCT/GB2020/052596
申请日：2020-10-15
申请人： UNIVERSITY OF ESSEX ENTERPRISES LIMITED
发明人： METODIEV, Metodi
IPC分类号： G01N33/68 , C07K1/14 , C12N9/00 , C12N15/62
摘要： Aspects of the present invention relate to method and systems which provide extended capability, compared to the existing techniques, for studying the important genome-proteome interactions and chromatin folding and dynamics in higher eukaryotes. Particularly, but not exclusively, the present invention relates to a system involving the CRISPR/ Cas gene editing technology in combination with one or more protein identification techniques based on proximity biotinylation. Certain embodiments involve the use of quantitative mass spectrometry, and/ or next-generation sequencing.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式